Author:
Zhou Yi-Han,Yu Lu-Ting,Wang Xiao-Nan,Li You-Jie,Xu Ke-Yi,Li Xin,Pu Chun-Cheng,Xie Fei-Lu,Xie Bing-Bing,Gao Yan,Luo Chen
Funder
Science and Technology Program of Suzhou
China Postdoctoral Science Foundation
Graduate Research and Innovation Projects of Jiangsu Province
National Natural Science Foundation of China
Reference39 articles.
1. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial;Russell-Jones;Lancet,2023
2. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes;Kutz;Diabetes Care,2023
3. Recent developments in adjunct therapies for type 1 diabetes;Timmons;Expert Opin. Invest. Drugs,2022
4. Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions;Rickels;Endocr. Rev.,2019
5. RegII is a beta-cell protein and autoantigen in diabetes of NOD mice;Gurr;Diabetes,2007